Oncologists at the FDA have warned that higher doses of targeted drugs and biologic therapies for solid and haematological cancers are not necessarily more effective than lower doses. Writing in a Perspective article in the NEJM, they said it was not unusual for doses and schedules of oncology drugs to be inadequately characterised before sponsors ...
More is not always better with targeted cancer drug dose selection
By Mardi Chapman
18 Oct 2021